Nanobiotix (ADR)
Develops radiotherapy-activated nanoparticle candidates for solid tumors.
Something off on this page? Send us feedback.
Profile
Develops radiotherapy-activated nanoparticle candidates, led by JNJ-1900 (NBTXR3), alongside the Curadigm Nanoprimer and Oocuity platforms. The late-clinical business relies on global development with Janssen/Johnson & Johnson for its lead program.
Develops three nanotechnology platforms for oncology and related therapeutic applications. Its lead candidate, JNJ-1900 (NBTXR3), is a functionalized hafnium-oxide nanoparticle given by a one-time intratumoral injection and activated by radiotherapy. It is being studied in solid tumors, including head-and-neck cancer and inoperable stage 3 non-small-cell lung cancer.
Curadigm Nanoprimer is an earlier-stage platform supporting an internal pipeline and external collaborations. Oocuity is a third platform, with no commercial product identified in the current materials.
The business remains a late-clinical platform and pipeline operation rather than a mature product franchise. Clinical progress for JNJ-1900 is tied to the global Janssen/Johnson & Johnson collaboration, which has assumed NANORAY-312 sponsorship in most regions.
Company facts
Key statistics
Year to date +85.6% · Average volume (30d) 161.6K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Jun 4, 2026 | Leerink Partners | Reiterate | Outperform | $26 | $46 |
| May 1, 2026 | UBS | Reiterate | Neutral | $30 | |
| Nov 25, 2025 | Leerink Partners | Target | $14 | $26 | |
| Sep 18, 2025 | Leerink Partners | Target | $14 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Mar 31, 2026Q4 FY25 | $0.30 | −$0.46 | −250.7% | $51.5M | $3.5M | −93.2% | +10.37% |
| Sep 30, 2025Q2 FY25 | −$0.25 | −$0.13 | +45.9% | $23.9M | $31.4M | +31.2% | −0.79% |
| Apr 2, 2025Q4 FY24 | −$0.62 | −$1.01 | −63.5% | $3.6M | −$21.6M | −709.2% | −0.59% |
| Nov 12, 2024 | −$0.51 | −$0.50 | +2.5% | $10.3M | $10.0M | −3.5% | −2.98% |
Financial highlights
| 12 quarters | Q2 FY23 | Q4 FY23 | Q2 FY24 | Q4 FY24 | Q2 FY25 | Q4 FY25 | |
|---|---|---|---|---|---|---|---|
| Revenue | $3.8M | $38.1M | $10.8M | −$19.1M | $30.9M | $3.5M | |
| Gross profit | $3.8M | $38.1M | $10.8M | −$19.1M | $30.9M | $3.5M | |
| Operating income | −$29.4M | −$1.6M | −$27.4M | −$51.8M | $936.2K | −$13.5M | |
| Net income | −$32.6M | −$13.4M | −$25.3M | −$53.6M | −$6.2M | −$21.5M | |
| Diluted EPS | −$0.93 | −$0.36 | −$0.53 | −$1.14 | −$0.13 | −$0.45 | |
| Gross margin | 100.0% | 100.0% | 100.0% | — | 100.0% | 100.0% | |
| Operating margin | -770.4% | -4.3% | -254.6% | — | 3.0% | -386.9% |
Revenue by product · FY25
Balance sheet, Dec 31, 2025Cash & short-term investments $61.1M · Total debt $110.4M · Total assets $78.5M · Shareholders' equity −$97.9M
Dividends
No dividends on record.
Ownership
Shares outstanding 50.60M · Float 41.45M · 81.9% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Johnson & Johnson | 5.62M | 11.11% | 13F | May 13, 2026 |
| Invus Public Equities, L.P. | 4.23M | 8.90% | 13G | Apr 17, 2025 |
| Morgan Stanley | 36.3K | 0.07% | 13F | May 15, 2026 |
| Optiver Holding B.V. | 13.5K | 0.03% | 13F | Jun 2, 2026 |
| Marshall Wace, LLP | 9.2K | 0.02% | 13F | May 15, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
View detailsPeers
- Alpha Tau Medical
Intratumoral alpha radiation in overlapping HNSCC development
- Merck
PD-1 therapy used with radiotherapy in locally advanced HNSCC
- Bicara Therapeutics
Phase 3 EGFR/TGF-β therapy for HPV-negative HNSCC
- PDS Biotechnology
Phase 3 HPV16-positive HNSCC immunotherapy candidate
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Nanobiotix (ADR) | $40.83 | −0.61% | $2.09B | — | — | 62.1 | — |
| Alpha Tau Medical | $14.85 | +1.23% | $1.32B | — | — | — | — |
| Merck | $148.19 | −0.08% | $366.18B | 118.7 | 17.2 | 5.5 | +5.1% |
| Bicara Therapeutics | $23.43 | +0.06% | $1.54B | — | — | — | — |
| PDS Biotechnology | $0.2136 | +2.05% | $11.8M | — | — | — | — |
| Median | 118.7 | 17.2 | 5.5 | +5.1% |